[{"id":"c61b43a4-2a89-4473-ab82-c58710ea7ecb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01995188","created_at":"2021-01-18T09:06:07.738Z","updated_at":"2024-07-02T16:37:17.324Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01995188","lead_sponsor":"Genentech, Inc.","biomarkers":" EGFR • ALK • SLC34A2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • ALK • SLC34A2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • lifastuzumab vedotin (DNIB0600A)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 12/16/2013","start_date":" 12/16/2013","primary_txt":" Primary completion: 11/09/2016","primary_completion_date":" 11/09/2016","study_txt":" Completion: 11/09/2016","study_completion_date":" 11/09/2016","last_update_posted":"2017-10-04"}]